maritide obesity news

What's Next for Amgen Obesity Drug

New Obesity Drug MariTide Helps Patients Lose Up to 20% of Weight, Early Data Shows

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month,

CNBC on MSN · 4d

Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other experimental treatments.

Newsweek · 4d

What's Next for Amgen Obesity Drug After Investors Disappointed by Results

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

15hon MSN

Eli Lilly and Novo Nordisk’s Obesity Moat Just Got Stronger

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

pharmaphorum3d

Amgen's big reveal of obesity data falls a bit flat

William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...

Daily22h

Maritide effects robust weight loss in people living with obesity or overweight at 52 weeks in a phase 2 study

According to phase 2 study, MariTide achieved significant weight loss in individuals with obesity or overweight, with up to ...

Amgen’s MariTide Phase 2 Success Drives Buy Rating Amid Promising Obesity Treatment Prospects

Goldman Sachs analyst Salveen Richter has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday.Don't Miss our Black ...

Amgen: MariTide Underwhelms, But There Are Ways To Win

Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even without the full upside from MariTide.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results